Hikma Pharmaceuticals Plc Notice of Results (6569F)
19 Luglio 2021 - 10:27AM
UK Regulatory
TIDMHIK
RNS Number : 6569F
Hikma Pharmaceuticals Plc
19 July 2021
London, 19 July , 2021 - Hikma Pharmaceuticals PLC (Hikma), will
announce its interim financial results for the six months ended 30
June 2021 on Friday 6 August 2021.
A recording of the presentation will be available on the
Company's website at www.hikma.com from 8:00am BST. Hikma will also
host a webinar with a live Q&A for analysts and investors at
9:30am BST, and a recording will be available on the Company's
website later that day.
Please register your attendance in advance by clicking here:
https://hikma.zoom.us/webinar/register/WN_wugtG0VQTwm8c5b5FM8e5A.
For further information please contact Tiina Lugmayer -
tlugmayer@hikma.com.
- ENDS -
Enquiries
Hikma (Investors):
Susan Ringdal
EVP, Strategic Planning and Global +44 (0)20 7399 2760/ +44 (0)7776
Affairs 477050
Guy Featherstone +44 (0)20 3892 4389/ +44 (0)7795
Senior Investor Relations Manager 896738
Layan Kalisse +44 (0)20 7399 2788/ +44 (0)7970
Investor Relations Analyst 709912
Teneo (Press):
Charles Armitstead / Claire Scicluna +44 (0)7703 330 269/ +44
(0)7385 395 028
About Hikma
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the United States (US), the
Middle East and North Africa (MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,400 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and
Ba1/stable Moody's)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORZZGMNRLFGMZG
(END) Dow Jones Newswires
July 19, 2021 04:27 ET (08:27 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024